2 Top Stories Affecting Dow 30 Healthcare Stocks This Week

Shares of the Israeli pharmaceutical firm Protalix BioTherapeutics (AMEX:PLX) have taken off, following the website Calcalist reporting that the company is in discussions to be purchased for $1 billion. Pfizer has shown interest in acquiring Protalix, but at a valuation below the amount that Protalix prefers, says the website, which adds that Protalix’s board has chosen Citigroup (NYSE:C) to manage the selling process.